Julia Dragich
Nurse Practitioner · Kansas City, KSNPI 1649662180
Payments from drug & device makers
Across 130 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$709
- Lilly USA, LLC$328
- Astellas Pharma US Inc$261
- Abbott$133
- Amgen$94
- Novo Nordisk$82
- plus $382 from 17 others
What the payments were for
- Food & beverage$1,97899%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $709 |
| Lilly USA, LLC | 18 | $328 |
| Astellas Pharma US Inc | 11 | $261 |
| Abbott | 6 | $133 |
| Amgen | 6 | $94 |
| Novo Nordisk | 5 | $82 |
| Organon | 3 | $72 |
| Hologic Sales And Service, LLC | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $27 |
| Averitas Pharma Inc. | 1 | $27 |
| AstraZeneca | 2 | $26 |
| Phadia US Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| GSK | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Bayer | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Pfizer | 1 | $14 |
| Merck | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $13 |
How this compares
$1,990 in reported general payments places this provider in the 85th percentile of 1,326 nurse practitioner providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $48,172 |
| OzempicSemaglutide | 24 | $33,992 |
| EliquisApixaban | 32 | $30,151 |
| JardianceEmpagliflozin | 22 | $25,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $24,909 |
| LinzessLinaclotide | 16 | $18,715 |
| MyrbetriqMirabegron | 17 | $15,837 |
| TradjentaLinagliptin | 11 | $14,128 |
| JanuviaSitagliptin Phosphate | 15 | $12,764 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $12,412 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,616 |
| Atorvastatin Calcium | 253 | $2,191 |
| Gabapentin | 136 | $2,090 |
| Pregabalin | 35 | $1,496 |
| Nebivolol Hcl | 15 | $1,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $328 | $48,17232 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $19 | $37,32168 claims |
| Novo NordiskOzempic | $82 | $33,99224 claims |
| PfizerEliquis | $14 | $30,15132 claims |
| AbbVieLinzess | $709 | $18,71516 claims |
| Astellas Pharma US IncMyrbetriq | $261 | $15,83717 claims |
| MerckJanuvia | $14 | $12,76415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Kansas City
- Sarah FitzmauriceKansas City$247K
- Dana MillerKansas City$13K
- Jason OralloKansas City$10K
- Ashlee OrndorffKansas City$7K
- Paul WohletzKansas City$6K
- Emily OstranderKansas City$5K
- Gary GrafTopeka$726K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.